ABOUT US

SENIOR MANAGEMENT TEAM

Joseph S. Zakrzewski - CEO
Mr. Zakrzewski joined Amarin in January 2010 as Executive Chairman. Mr. Zakrzewski has more than 20 years of industry experience, including significant contributions to Reliant Pharmaceuticals as Chief Operating Officer during the period when Omacor®/Lovaza® was successfully developed, launched, and marketed for reducing very high triglyceride levels, leading to its 2007 acquisition by GlaxoSmithKline. In addition, Mr. Zakrzewski contributed 17 years of service to Eli Lilly & Company in a variety of capacities, including Vice President of Corporate Business Development where he had global responsibility for licensing activities.

John Thero - President
Mr. Thero has more than 20 years of senior financial and operational management experience including over 15 years supporting the growth of life science companies. Previously, Mr. Thero was Chief Financial Officer of Amarin Corporation. Prior to Amarin, Mr. Thero was the Chief Financial Officer at ViaCell, Inc., where he helped guide the company to its successful sale, and Abiomed, Inc., during its transition from a development-stage company into a commercial entity. Mr. Thero began his professional career at Arthur Andersen LLP, during which time he became a Certified Public Accountant.

Paul Huff - Chief Commercial Officer
Mr. Huff joined Amarin in 2010 as Chief Commercial Officer and brings over 25 years of cardiovascular-focused pharmaceutical marketing and sales experience, with a special emphasis on marketing lipid-modifying prescription pharmaceuticals. Mr. Huff has held senior-level sales and marketing positions with a number of pharmaceutical and biotechnology companies, including Reliant Pharmaceuticals, where as Vice President of Marketing, he played a pivotal role in the launch and successful commercialization of Lovaza, the leading prescription Omega-3 product for reducing triglycerides. Similarly, at Kos Pharmaceuticals Mr. Huff played an integral role in the launch and successful commercialization of Niaspan, the leading prescription drug for raising HDL cholesterol. Mr. Huff received a B.S. in marketing from the University of Maryland.

Declan Doogan, M.D. - Chief Medical Officer
Dr. Doogan joined Amarin in April 2007 as Head of Research and Development and was appointed Interim Chief Executive Officer in October 2009. Most recently, Dr. Doogan was Senior Vice President and Head of Worldwide Development at Pfizer Global Research & Development. In recent years, he held a number of senior positions in Pfizer in the US and the UK. Dr. Doogan joined Pfizer in 1982, where he led the Zoloft clinical development program. He held positions in the UK and in Japan, where he was initially Medical Director and later head of the company’s development organization. Dr. Doogan holds a Visiting Professorship of Drug Development Science with Kitasato University in Japan. In addition, Dr. Doogan holds a number of non-executive directorships in the US and the UK. Dr. Doogan received his medical degree from Glasgow University in 1975. He is a Fellow of the Royal College of Physicians of Glasgow and the Faculty of Pharmaceutical Medicine in the UK.

Stuart Sedlack – SVP, Corporate Development
Mr. Sedlack is an accomplished corporate development executive with over 20 years of licensing, corporate development and finance experience and is responsible for Amarin's business development and supply chain activities. Prior to joining Amarin in 2007, he held several senior level positions in industry including SVP, Corporate Development, Global Head Negotiations, Infectious Diseases, and VP, Corporate Development with Alba Therapeutics, Novartis Pharma AG, and Élan Corporation, plc, respectively. Prior to Élan, he served as Director at the University of Maryland Medical System's technology licensing office and began his career in 1988 working for ABN AMRO Bank and MNC International Bank specializing in international trade finance. Mr. Sedlack holds a BS degree from the University of Richmond and an MBA from Babson College.

Paresh Soni, M.D., PhD - SVP and Head of Development
Dr. Paresh Soni joined Amarin in September 2008 as SVP and Head of Development. Dr. Soni joins Amarin from Pfizer where he held a number of leadership roles in Pfizer Global Research and Development in both experimental medicine and late stage development. He provided clinical leadership to a number of programs including darifenacin, Viagra and lasofoxifene, including the submission of two New Drug Applications (NDAs). He was the development team leader for antiviral projects in infectious diseases, and clinical leader and clinical group head for the GI/hepatology therapeutic area. Dr. Soni, a board-certified internist and gastroenterologist, completed his medical and specialist training at the University of Natal in South Africa before completing a research fellowship at the Division of Hepatology, Royal Free Hospital School of Medicine, London, where he also completed a PhD. Dr. Soni is a member of the American Gastroenterology Association (AGA) and American Association for the Study of Liver Diseases (AASLD).

Joseph T. Kennedy – SVP, General Counsel
Mr. Kennedy joined Amarin in December 2011 with a significant record of achievement in the life science industry. Mr. Kennedy was previously Vice President, General Counsel and Secretary of Transcept Pharmaceuticals, Inc., Chief Corporate Counsel, then Vice President, Acting Chief Legal Officer with Eyetech Pharmaceuticals, Inc., and Vice President and U.S. Counsel, Corporate Business Development, with Elan Corporation, plc. Mr. Kennedy previously practiced law with Orrick, Herrington & Sutcliffe LLP. Mr. Kennedy earned a J.D. from New York Law School and a B.A. in Economics from Fairfield University. In 2010, he was honored by the President of Ireland for his contributions to the life science industry as one of the "Irish Life Science 50."

This page was last updated on December 19, 2011